7 Results
April 2023
NIAID Marks World Malaria Day
April 25, 2023
World Malaria Day is an opportunity to reflect on continuing challenges posed by malaria and reaffirm a commitment to overcoming them. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, joins with the global health community in recognizing this year’s theme of “Time to Deliver on Zero Malaria: Invest, Innovate, Implement.”
October 2022
Monoclonal Antibody Prevents Malaria Infection in African Adults
October 31, 2022
One dose of an antibody drug safely protected healthy, non-pregnant adults from malaria infection during an intense six-month malaria season in Mali, Africa, a National Institutes of Health clinical trial has found. The antibody was up to 88.2% effective at preventing infection over a 24-week period, demonstrating for the first time that a monoclonal antibody can prevent malaria infection in an endemic region.
August 2022
Monoclonal Antibody Prevents Malaria in U.S. Adults, NIH Trial Shows
August 4, 2022
One injection of a candidate monoclonal antibody (mAb) known as L9LS was found to be safe and highly protective in U.S. adults exposed to the malaria parasite, according to results from a National Institutes of Health Phase 1 clinical trial published in The New England Journal of Medicine.
April 2022
NIAID Marks World Malaria Day
April 25, 2022
Malaria is one of the world’s most widespread and ancient infectious diseases, and controlling it remains a critical public health priority. This complex parasitic disease, transmitted from person to person by the bite of infected mosquitoes, threatens the lives and livelihoods of millions of people in tropical areas around the globe. Each year, on April 25, World Malaria Day provides an opportunity to reflect on recent advances in controlling this disease and the challenges that remain.
August 2021
Monoclonal Antibody Prevents Malaria in Small NIH Trial
August 11, 2021
One dose of a new monoclonal antibody discovered and developed at the National Institutes of Health safely prevented malaria for up to nine months in people who were exposed to the malaria parasite. The small, carefully monitored clinical trial is the first to demonstrate that a monoclonal antibody can prevent malaria in people. The trial was sponsored and conducted by scientists from the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, and was funded by NIAID.
June 2021
Investigational Malaria Vaccine Gives Strong, Lasting Protection
June 30, 2021
Two U.S. Phase 1 clinical trials of a novel candidate malaria vaccine have found that the regimen conferred unprecedentedly high levels of durable protection when volunteers were later exposed to disease-causing malaria parasites. The vaccine combines live parasites with either of two widely used antimalarial drugs—an approach termed chemoprophylaxis vaccination. A Phase 2 clinical trial of the vaccine is now underway in Mali, a malaria-endemic country.
January 2020
First Human Trial of Monoclonal Antibody to Prevent Malaria Opens
January 27, 2020
A Phase 1 clinical trial testing the safety and effectiveness of a monoclonal antibody (mAb) against malaria has begun enrolling healthy adult volunteers at the National Institutes of Health Clinical Center in Bethesda, Maryland. The trial, sponsored by NIH’s National Institute of Allergy and Infectious Diseases (NIAID), is the first to test mAb CIS43LS in humans. It aims to enroll up to 73 volunteers aged 18 through 50 years old who have never had malaria.
